.png){kind=icon}
.png){kind=icon}
Return
Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial
.png){kind=icon}
OA
AI
L
R
R
S
A
G
A
T
DOI：10.1111/apt.70775.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD) and impairs quality of life. Hepcidin, the regulator of systemic iron homeostasis, may predict response to iron therapy; however, its utility in IBD remains unclear. This study evaluated whether baseline hepcidin predicts response to oral and intravenous (IV) iron in active IBD to guide personalised treatment.
Keywords:
anaemia
hepcidin
inflammatory bowel disease
iron deficiency
iron therapy
personalised medicine
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
A
IF:
6.7
Papers:
422
Citations:
0
Organization
Cited Papers